Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Oct 9;9(10):e109759.
doi: 10.1371/journal.pone.0109759. eCollection 2014.

The NPM1 mutation type has no impact on survival in cytogenetically normal AML

Friederike Pastore  1 , Philipp A Greif  1 , Stephanie Schneider  2 , Bianka Ksienzyk  2 , Gudrun Mellert  2 , Evelyn Zellmeier  2 , Jan Braess  3 , Cristina M Sauerland  4 , Achim Heinecke  4 , Utz Krug  5 , Wolfgang E Berdel  5 , Thomas Buechner  5 , Bernhard Woermann  6 , Wolfgang Hiddemann  1 , Karsten Spiekermann  1
Affiliations
Randomized Controlled Trial

The NPM1 mutation type has no impact on survival in cytogenetically normal AML

Friederike Pastore et al. PLoS One. .

Abstract

NPM1 mutations represent frequent genetic alterations in patients with acute myeloid leukemia (AML) associated with a favorable prognosis. Different types of NPM1 mutations have been described. The purpose of our study was to evaluate the relevance of different NPM1 mutation types with regard to clinical outcome. Our analyses were based on 349 NPM1-mutated AML patients treated in the AMLCG99 trial. Complete remission rates, overall survival and relapse-free survival were not significantly different between patients with NPM1 type A or rare type mutations. The NPM1 mutation type does not seem to play a role in risk stratification of cytogenetically normal AML.

Trial registration: ClinicalTrials.gov NCT00266136.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Overall Survival (OS) and Relapse-Free Survival (RFS) in 349 patients with cytogenetically normal acute myeloid leukemia and NPM1 mutation treated in the AMLCG99 study.
(A) OS in patients with NPM1 type A mutation versus NPM1 rare type mutation. (B) OS in patients with NPM1 type A mutation versus NPM1 rare type mutation with or without an additional FLT3-ITD. (C) RFS in patients with NPM1 type A mutation versus NPM1 rare type mutation. (D) RFS in patients with NPM1 type A mutation versus NPM1 rare type mutation with or without an additional FLT3-ITD. Abbreviations: CR, complete remission; FLT3-ITD+, presence of an internal tandem duplication in the fms-related tyrosine 3 gene; FLT3-ITD-, absence of an internal tandem duplication in the fms-related tyrosine 3 gene; NPM1-A, mutation in the nucleophosmin gene consisting of an insertion of the tetranucleotide TCTG; NPM1-RA, mutation in the nucleophosmin gene other than type A.
Figure 2
Figure 2. Overall Survival (OS) and Relapse-Free Survival (RFS) in 349 patients with cytogenetically normal acute myeloid leukemia and NPM1 mutation treated in the AMLCG99 study.
(A) OS in patients with NPM1 type A mutation versus NPM1 type B mutation versus NPM1 type D mutation versus NPM1 type other mutation. (B) RFS in patients with NPM1 type A mutation versus NPM1 type B mutation versus NPM1 type D mutation versus NPM1 type other mutation. Abbreviations: CR, complete remission; FLT3-ITD+, presence of an internal tandem duplication in the fms-related tyrosine 3 gene; FLT3-ITD-, absence of an internal tandem duplication in the fms-related tyrosine 3 gene; NPM1-A, mutation in the nucleophosmin gene consisting of an insertion of the tetranucleotide TCTG; NPM1-B, mutation in the nucleophosmin gene consisting of an insertion of the tetranucleotide CATG, NPM1-D, mutation in the nucleophosmin gene consisting of an insertion of the tetranucleotide CCTG, NPM1-other, mutation in the nucleophosmin gene other than NPM1 mutation types A, B, D.
See this image and copyright information in PMC

References

    1. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, et al. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352: 254–266 10.1056/NEJMoa041974 - DOI - PubMed
    1. Federici L, Falini B (2013) Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization. Protein Sci 22: 545–556 10.1002/pro.2240 - DOI - PMC - PubMed
    1. Falini B, Bolli N, Shan J, Martelli MP, Liso A, et al. (2006) Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 107: 4514–4523 10.1182/blood-2005-11-4745 - DOI - PubMed
    1. Koh Y, Park J, Bae EK, Ahn KS, Kim I, et al. (2009) Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype. Int J Hematol 90: 1–5. - PubMed
    1. Alpermann T, Haferlach C, Dicker F, Eder C, Kohlmann A, et al. (2013) Evaluation Of Different NPM1 Mutations In AML Patients According To Clinical, Cytogenetic and Molecular Features and Impact On Outcome. Blood 122: 51–51 Available: http://bloodjournal.hematologylibrary.org/content/122/21/51.abstract.

Publication types

MeSH terms

Associated data

LinkOut - more resources